News articles about TRACON Pharmaceuticals (NASDAQ:TCON) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TRACON Pharmaceuticals earned a news impact score of 0.17 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.2838519309109 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

TRACON Pharmaceuticals (NASDAQ:TCON) remained flat at $$3.50 during trading on Thursday. 144,800 shares of the company traded hands, compared to its average volume of 238,700. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.80 and a quick ratio of 3.80. The firm has a market capitalization of $60.85 and a P/E ratio of -2.87. TRACON Pharmaceuticals has a 52 week low of $2.00 and a 52 week high of $5.70.

TRACON Pharmaceuticals (NASDAQ:TCON) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.32. The business had revenue of $7.50 million during the quarter, compared to analysts’ expectations of $7.60 million. TRACON Pharmaceuticals had a negative net margin of 201.21% and a negative return on equity of 83.43%. analysts expect that TRACON Pharmaceuticals will post -1.21 earnings per share for the current year.

Separately, Zacks Investment Research cut shares of TRACON Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact TRACON Pharmaceuticals (TCON) Share Price” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/04/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-tracon-pharmaceuticals-tcon-share-price.html.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

Insider Buying and Selling by Quarter for TRACON Pharmaceuticals (NASDAQ:TCON)

Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.